Xlife Sciences AG (XLS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Xlife Sciences AG (XLS) has a cash flow conversion efficiency ratio of -0.003x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF-803.62K ≈ $-1.02 Million USD) by net assets (CHF303.42 Million ≈ $383.60 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Xlife Sciences AG liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Xlife Sciences AG - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Xlife Sciences AG's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Xlife Sciences AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xlife Sciences AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Taiwan Fructose Co Ltd
TWO:4207
|
0.033x |
|
Greystone Housing Impact Investors LP
NYSE:GHI
|
0.023x |
|
SENFONG
KLSE:5308
|
-0.163x |
|
Siam Wellness Group Public Company Limited
BK:SPA
|
0.119x |
|
Admiral Group PLC
LSE:ADM
|
0.350x |
|
Grammer AG
XETRA:GMM
|
-0.141x |
|
Nakamoto Inc.
NASDAQ:NAKA
|
-0.015x |
|
SRM CONTRACTORS ORD (BSE)
NSE:SRM
|
-0.025x |
Annual Cash Flow Conversion Efficiency for Xlife Sciences AG (2019–2024)
The table below shows the annual cash flow conversion efficiency of Xlife Sciences AG from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Xlife Sciences AG.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CHF305.26 Million ≈ $385.93 Million |
CHF-421.51K ≈ $-532.90K |
-0.001x | -315.57% |
| 2023-12-31 | CHF268.17 Million ≈ $339.04 Million |
CHF171.78K ≈ $217.18K |
0.001x | +103.27% |
| 2022-12-31 | CHF235.23 Million ≈ $297.40 Million |
CHF-4.61 Million ≈ $-5.83 Million |
-0.020x | +4.32% |
| 2021-12-31 | CHF211.23 Million ≈ $267.06 Million |
CHF-4.32 Million ≈ $-5.47 Million |
-0.020x | -563.59% |
| 2020-12-31 | CHF130.17 Million ≈ $164.57 Million |
CHF-401.55K ≈ $-507.67K |
-0.003x | +24.57% |
| 2019-12-31 | CHF97.38 Million ≈ $123.11 Million |
CHF-398.24K ≈ $-503.48K |
-0.004x | -- |
About Xlife Sciences AG
Xlife Sciences AG focuses on the development and commercialization of research projects in the life sciences sector. The company's project covers technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health areas that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data. It also produces, … Read more